Related by context. All words. (Click for frequent words.) 70 MAGE A3 ASCI 69 AAG geldanamycin analog 69 pan HDAC inhibitor 69 HSP# inhibitor 69 CYT# potent vascular disrupting 68 interferon gamma 1b 68 AGHD 68 liposomal formulation 68 Xanafide 68 viral kinetics 68 IL# PE#QQR 68 depsipeptide 67 preclinical efficacy 67 pharmacodynamic properties 67 somatostatin analog 67 oral prodrug 67 YONDELIS 67 PROVENGE sipuleucel T 67 fosbretabulin 67 PSMA ADC 67 novel peptide 67 vapreotide acetate 67 Silodosin 67 beta 1a 67 teriflunomide 66 pharmacodynamic markers 66 vinca alkaloid 66 CCX# 66 HCV NS5B polymerase 66 cannabinor 66 ARIKACE ™ 66 Tyrosine Kinase Inhibitor 66 orally inhaled migraine 66 R roscovitine 66 evaluating tivozanib 66 generation purine nucleoside 66 Fc fusion protein 66 ocular formulation 66 ENMD # 66 HyQ 66 trastuzumab Herceptin R 66 plasma kallikrein inhibitor 66 vitro cytotoxicity 66 HGS ETR2 66 topoisomerase II inhibitor 66 histone deacetylase HDAC inhibitor 66 histone deacetylase inhibitor 66 novel histone deacetylase 66 HCV replicon 66 Telintra 66 sipuleucel T 66 TRX1 66 Trandolapril 66 erlotinib Tarceva ® 66 IMiDs ® 66 ongoing Phase 1b 65 Hsp# Inhibitor 65 Androxal TM 65 trastuzumab emtansine T DM1 65 mertansine 65 mGluR5 antagonists 65 Presents Preclinical 65 busulfan 65 adecatumumab MT# 65 Anavex #-# 65 non nucleoside inhibitor 65 Aflibercept 65 dasatinib Sprycel 65 preclinically 65 Fludara ® 65 favorable pharmacokinetic profile 65 Initiates Enrollment 65 pharmacokinetic PK study 65 small molecule tyrosine 65 eTag assays 65 riociguat 65 Initiates Clinical Trial 65 nucleotide analog 65 Seliciclib 65 pharmacodynamic parameters 65 pharmacokinetic characteristics 65 Panzem R NCD 65 RNA antagonist 65 MGd 65 Zalypsis 65 demonstrated antitumor activity 65 pharmacokinetic equivalence 65 CA9 SCAN 65 ON #.Na 65 Completes Patient Enrollment 65 cMET 65 BACcel ™ system 65 delafloxacin 65 phase IIb study 65 bortezomib Velcade 65 sorafenib tablets 65 #nd EORTC NCI 65 KRN# 65 novel VDA molecule 65 PEG SN# 65 compound AEZS 65 Octreolin 65 TLR9 agonist 64 Degarelix 64 PEGylated anti 64 mitogen activated ERK kinase 64 RhuDex R 64 thalidomide Thalomid 64 EGS# 64 K ras mutations 64 Romiplostim 64 selective modulator 64 FOLFOX6 chemotherapy regimen 64 Phase #b/#a clinical 64 Phase Ib study 64 nonclinical studies 64 trastuzumab DM1 T DM1 64 Presents Preclinical Data 64 CINQUIL 64 Temsirolimus 64 antidepressant efficacy 64 candidate CRLX# 64 relapsed MM 64 Zybrestat 64 Pharmacodynamic 64 HER2 ErbB2 64 phase IIIb 64 Vidaza azacitidine 64 EGFR TKI 64 peptide conjugated 64 tropism testing 64 Poly ICLC 64 cytokine refractory 64 preclinical pharmacokinetic 64 virus HCV protease inhibitor 64 hyaluronidase enzyme 64 ospemifene 64 indibulin 64 PRT# 64 OMP #M# 64 orally dosed 64 Multiple Ascending Dose 64 neratinib 64 metastatic castration resistant 64 Cannabinor 64 urinary N telopeptide 64 HDL Selective Delipidation 64 taxane resistant 64 HER2 expression 64 Romidepsin 64 phase IIb clinical 64 targeting CD# 64 rxRNA 64 CG# [003] 64 Oral NKTR 64 alkylating agent 64 investigational humanized monoclonal antibody 64 vivo potency 64 Squalamine 64 fusion enhancers 64 castrate resistant prostate cancer 64 Rigel R# 64 pharmacodynamic biomarkers 64 CTAP# Capsules 64 anti amnesic 64 vidofludimus 64 PI3K/Akt pathway inhibitor 64 radezolid 64 GLP toxicology studies 64 metaglidasen 64 Ophena TM 64 generation antisense inhibitor 64 NU# direct 64 proteasome inhibitor 64 Kahalalide F 64 PEGylated interferon beta 1a 64 JVRS 64 Omacetaxine mepesuccinate 64 somatostatin analogue 64 VitiGam 64 topical gel formulation 64 PDE4 inhibitor 64 Liposomal 64 selective estrogen receptor modulator 64 sorafenib Nexavar 64 midstage clinical 64 MEK Inhibitor 64 CIMZIA TM certolizumab pegol 64 myeloproliferative diseases 64 Teriflunomide 64 PDE# inhibitors 63 CRMD# 63 selective kinase inhibitor 63 APOPTONE 63 SPRIX ® 63 Meets Primary Endpoint 63 Bezielle 63 Pemetrexed 63 plasma pharmacokinetics 63 genomic biomarker 63 Preclinical studies suggest 63 Trofex TM 63 OvaRex R 63 lumiliximab 63 Tarceva TM 63 Carfilzomib 63 EXPAREL TM 63 Pimavanserin 63 5 Fluorouracil 63 Initiates Phase II 63 AEGR 63 ZYBRESTAT fosbretabulin 63 acetonide FA 63 systemically administered 63 TBC# 63 varespladib 63 EDEMA3 trial 63 sodium glucose cotransporter 63 lexidronam injection 63 CaPre TM 63 hypoxia activated prodrug 63 orally administered inhibitor 63 SinuNase TM 63 Zemplar Capsules 63 A3 adenosine receptor 63 resolvin 63 TLR9 agonists 63 Belimumab 63 multicenter Phase II 63 RezularTM 63 p# inhibitor 63 refractory chronic lymphocytic 63 Anticalins ® 63 crizotinib PF # 63 Non inferiority 63 Orally administered 63 TNF Tumor Necrosis Factor 63 oral picoplatin 63 IFN α 63 Vernakalant 63 dose escalation clinical 63 aurora kinase 63 oral JAK1 63 Talabostat 63 galiximab 63 Kuvan sapropterin dihydrochloride 63 phase III isavuconazole 63 Elagolix 63 bevacizumab Avastin ® 63 Tasimelteon 63 including eniluracil ADH 63 HCV protease inhibitors 63 Sapacitabine 63 chimeric monoclonal antibody 63 IMA# 63 Amrubicin 63 CEQ# 63 Zenvia ™ 63 Begins Dosing 63 orally bioavailable 63 HERmark assay 63 SinuNase ™ 63 CCR5 antagonist 63 Aganocide ® 63 HIF PH inhibitors 63 IMiDs R 63 Phase #b/#a trial 63 Lenocta 63 TO AVOID PREGNANCY WHILE 63 mediated inhibition 63 serine protease inhibitor 63 selective agonist 63 XOMA 3AB 63 G#DT 63 intradermal injections 63 epigenetic therapies 63 Vidofludimus 63 PEGylated Fab fragment 63 EGFR HER2 63 DEB# 63 novel emulsion formulation 63 ORAL Sync 63 cyclophilin inhibitor 63 humanised monoclonal antibody 63 Solazed TM 63 PEGylated irinotecan 63 LB# [003] 63 HCV SPRINT 63 tumor specific antigen 63 Safinamide 63 trastuzumab Herceptin ® 63 nucleoside analog 63 Cardiotoxicity 63 histone deacetylase HDAC 63 SPRYCEL ® 63 cleavable linker 63 DCCR 63 benign prostatic hypertrophy BPH 63 non nucleoside 63 huC# DM4 63 Achieves Primary Endpoint 63 Known hypersensitivity 63 Sanvar R 63 Prostate AdenoCarcinoma Treatment 63 Initiates Clinical 63 5alpha reductase 63 Telatinib 63 GLYX 63 Vascugel 63 GRNVAC1 63 NB S# strontium malonate 63 Azacitidine 63 Azedra 63 LHRH receptor positive 63 CANCIDAS 63 CD# CEA 63 Randomized Phase 63 Pyridorin 63 JAK inhibitor 63 MTP inhibitor 63 Tezampanel 63 RhuDex ® 63 highly selective inhibitor 63 cetuximab Erbitux R 63 KSP inhibitor 63 reversible inhibitor 63 solithromycin 63 Pertuzumab 63 selective antagonist 63 GSK# [002] 63 TRACON Pharmaceuticals 63 rhIGFBP 3 63 mTOR inhibitors 63 Quinamed 63 HuMax EGFr 63 immunomodulation 63 mGluR5 NAM 63 PEGylated interferon 63 Androgen Receptor 62 peripherally acting 62 relapsed MCL 62 lintuzumab SGN 62 docetaxel Taxotere ® 62 ELACYT 62 cisplatin gemcitabine 62 Thiovir 62 elotuzumab 62 PI3K/mTOR 62 selective androgen receptor modulator 62 Haptoglobin 62 Nasdaq DVAX 62 Panzem NCD 62 Pivotal Phase III 62 NV1FGF 62 bosutinib 62 Hedgehog inhibitor 62 recurrent glioblastoma multiforme 62 5 FU leucovorin 62 Factor VIIa 62 Omacetaxine 62 Guanilib 62 phase IIb trial 62 selective inhibition 62 HDAC Inhibitor 62 Ozarelix 62 ZOLINZA 62 ALN TTR# 62 Varespladib 62 NEUGENE antisense 62 dasatinib Sprycel ® 62 antiangiogenic agent 62 tolerability pharmacokinetics 62 programs visit http:/www.bionovo.com 62 AKT inhibitor 62 OncoVEX GM CSF 62 GHRH 62 Methylnaltrexone 62 Phase 1a clinical 62 docetaxel Taxotere R 62 antisense inhibitors 62 PI3K inhibitors 62 isatoribine 62 OvaRex ® MAb 62 dimeglumine 62 MET amplification 62 LHRH antagonists 62 Exelixis compounds 62 pharmacodynamic effects 62 LT NS# 62 ACAPODENE 62 PROSTASCINT R 62 generation Hsp# inhibitor 62 TLR antagonists 62 standard chemotherapy regimen 62 unresectable tumors 62 P#X# antagonist 62 interleukin IL -# 62 kidney urologic 62 Genasense ® oblimersen 62 investigational monoclonal antibody 62 DiLA2 62 PSN# [002] 62 RECOTHROM R 62 TLK# 62 statistically significant efficacy 62 ThermoDox ® clinical 62 Sudhir Agrawal D.Phil 62 Breast Cancer Assay 62 prostanoid 62 ExTRACT TIMI 62 BiTE R 62 antiangiogenic agents 62 chemosensitivity 62 Initiate Phase 62 incyclinide 62 gefitinib Iressa 62 mda 7 62 BRIM2 62 xenograft models 62 Enzyme Replacement Therapy 62 myelodysplastic myeloproliferative diseases 62 florbetaben 62 Maribavir 62 gemcitabine Gemzar 62 inhaled iloprost 62 Bafetinib 62 Spiegelmer ® 62 Preclinical Data 62 PEG IFN 62 Vaxfectin TM 62 AEG# 62 huN# DM1 62 ACAPODENE TM 62 Archexin 62 CORT # 62 small molecule thrombopoietin 62 pharmacodynamic profile 62 TÎ ² 4 62 Blinatumomab 62 YONDELIS R 62 Cervista HPV HR 62 Nilotinib 62 antiarrhythmic 62 intranasal formulation 62 Taxotere chemotherapy 62 pain palliation 62 potent topoisomerase II 62 Personalized Immunotherapy 62 Plicera 62 dextromethorphan quinidine 62 Nasdaq IDRA today 62 polymerase inhibitor 62 Phase #/#a trial 62 recurrent GBM 62 FOLOTYN ® 62 Pharmacokinetic parameters 62 potent suppressor 62 IRX 2 62 personalized dendritic 62 antitumor efficacy 62 Homspera TM 62 tumorigenicity 62 nalbuphine ER 62 Traficet EN 62 potent antiproliferative 62 MEK inhibitors 62 uricase 62 RGB # 62 Cytotoxic 62 Genz # 62 liposome encapsulated 62 small molecule activators 62 CRLX# 62 Dalbavancin 62 #D#C# 62 cardiac repolarization 62 Anticalin ® 62 CLARITY study 62 Phase Ib II 62 mGlu2 3 62 oral Hsp# inhibitor 62 Announces Poster Presentations 62 Enhanze Technology 62 Completes Dosing 62 OHR/AVR# 62 vascular disrupting agent 62 TRANSFORMS 62 CCR5 mAb 62 agonistic human 62 Trofex 62 lucinactant 62 inhibitor RG# 62 NS#/#A protease 62 Deforolimus 62 BRAF inhibitors 62 essential thrombocythemia ET 62 Iloperidone 62 clevidipine 62 phase IIa clinical 62 tumor histology 62 entinostat 62 pharmacokinetic PK profile 62 interferon alfa 2b 62 HGS ETR1 mapatumumab 62 Anticalin R 62 targeting PCSK9 62 secretory phospholipase A2 sPLA2 62 glutamic acid decarboxylase 62 partial agonist 62 pharmacodynamic PD 62 plasma renin activity 62 Tß4 62 radiation sensitizer 62 IMiDs ® compound 62 PROSTVAC TM 62 Aeolus Pharmaceuticals Announces 62 eprotirome 62 immunomodulating 62 hyperphenylalaninemia HPA due 62 Zevalin consolidation 62 pharmacologically active isomer 62 Nasdaq SGMO announced 62 Elvitegravir 62 Vidaza ® 62 Preclinical Study 62 PrevOnco 62 Aclidinium 62 pomalidomide 62 Phase #/#a 62 CINTREDEKIN BESUDOTOX 62 goserelin 62 Tesmilifene 62 EDEMA3 62 antiandrogen 62 isoform selective 62 basal bolus regimen 62 INSPIRE Trial Phase III 62 GW# [003] 62 coronary stent merged 62 Cleviprex TM clevidipine 62 PD LID 62 Tyrima 62 Therapeutic Competitors Companies 62 catheter occlusion 62 urocortin 2 62 successfully commercialize Iluvien 62 VEGFR2 inhibitor 62 markets Testim ® 62 HQK 62 omacetaxine mepesuccinate 62 Prodarsan ® 62 APTIMA HPV assay 62 HGS ETR1 62 GOUT 61 volociximab 61 Phase 2b Clinical Trial 61 targeted radiotherapeutic 61 SNT-MC#/idebenone 61 receptor tyrosine kinase inhibitor 61 PNP inhibitor 61 treat chronic sinusitis 61 dopamine D2 61 thymidylate synthase TS 61 Locked Nucleic Acid LNA 61 colorectal liver metastases 61 Cloretazine ® 61 oral salmon calcitonin 61 R lenalidomide 61 subtype selective 61 BRIM3 61 XL# inhibits 61 Tanespimycin 61 imatinib Gleevec ® 61 novel prodrug 61 Potelligent Technology 61 Cathepsin B 61 bovine thrombin 61 RECORD1 61 TKB# 61 ADP receptor antagonist 61 systemic RNAi therapeutic 61 RAV# 61 biologic DMARD 61 liposomal amphotericin B 61 protein tyrosine phosphatase 1B 61 candidates Azedra TM 61 HuLuc# 61 siRNAs targeting 61 receptor inhibitor 61 PORxin TM platforms 61 Angiotensin Converting Enzyme 61 EndoTAGTM 1 61 Glufosfamide 61 SAR# [004] 61 Oral Fingolimod 61 phase IIb III 61 TELINTRA R 61 BRAF inhibitor 61 Reports Preclinical Data 61 endothelin antagonists 61 visilizumab 61 alefacept 61 lanreotide 61 PRTX 61 alvespimycin 61 tumor xenograft models 61 developing Bicifadine serotonin 61 Presents Positive 61 HER2 overexpression 61 anti leukemic 61 ALN HTT 61 VFEND 61 recombinant PSMA vaccine 61 antiangiogenic therapy 61 Lu AA# 61 tigecycline 61 Ophena 61 myelofibrosis polycythemia vera 61 hypereosinophilic syndrome 61 ZK EPO 61 5 HT2A serotonin 61 BMS# 61 Randomized Phase II 61 Lisofylline LSF 61 hematological tumors 61 IgG1 monoclonal antibody 61 rhIGF-I/rhIGFBP-3 61 SUCCEED trial 61 novel topoisomerase 61 ACTEMRA TM 61 Saforis 61 Successfully Completes Phase 61 metastatic malignant 61 O PPDS 61 epithelial tumors 61 non nucleoside HCV 61 Solorel 61 Hsp# inhibitor 61 affinity ligands 61 anticancer compound 61 Adentri 61 LibiGel ® 61 EXPAREL ™ 61 antibody MAb 61 Mg Uk 61 therapeutic monoclonal antibody 61 Valdoxan 61 Combination REOLYSIN R 61 NeuroSTAT ® 61 telaprevir VX 61 effector function 61 platelet inhibitor 61 Ataluren 61 Posiphen 61 Granulocyte Colony Stimulating Factor 61 Alequel 61 Insulin PH# 61 brivaracetam 61 novel synthetic peptide 61 Phase IIA 61 humanized monoclonal 61 targeted antifolate 61 #beta HSD1 61 retaspimycin hydrochloride 61 diarrhea predominant irritable 61 TRAIL R1 61 TransVax TM 61 2 methoxyestradiol 61 peptidomimetic 61 developing Zerenex ferric 61 TRIOLEX HE# APOPTONE HE# 61 ritonavir boosted 61 microtubule inhibitor 61 TIMP 1 61 tubulin inhibitor 61 Epothilones 61 Hsp# inhibition 61 TELINTRA 61 Dasatinib 61 prospective multicentre 61 please visit www.advaxis.com 61 Fondaparinux 61 adecatumumab 61 2A receptor agonist 61 radiation dosimetry 61 Anticalins R 61 Proellex TM 61 mutated K ras 61 INCB# [001] 61 antifibrotic 61 controlled multicenter Phase 61 neuronal nicotinic receptor NNR 61 MPS IVA 61 Clinical Trial Results 61 JAK inhibitors 61 BIM #A# 61 Irinotecan 61 CIN2 + 61 XL# anticancer compounds 61 splice variants 61 Tolvaptan 61 GAMMAGARD 61 SPL# Gel vaginal microbicide 61 Targretin 61 PKC# 61 peptibody 61 DermaVir Patch 61 RRM1 61 Darinaparsin 61 synthetic retinoid 61 platform HDL Mimetic 61 PXD# 61 Vicriviroc 61 urate oxidase 61 Gleevec resistant 61 VEGF inhibitors 61 pathophysiological effects 61 PDX pralatrexate 61 R Saizen R 61 xanthine oxidase inhibitor 61 R sorafenib tablets 61 pharmacokinetic PK 61 Pivotal Phase 61 aurora kinase inhibitor 61 MCSP respectively 61 Novel Oral 61 mTOR inhibition 61 Panzem 61 topical gel containing 61 velafermin 61 EZN 61 Aplidin R 61 TRIOLEX ™ 61 Contrave# 61 PPAR gamma agonists 61 oral Azacitidine 61 Aurora Kinase 61 non porcine pancreatic 61 peptide antigens 61 JAK2 inhibitor 61 retaspimycin 61 aplindore 61 LEVADEX ™ 61 CBLC# 61 abnormal p# 61 GVAX ® 61 vascular disrupting agents 61 Gamunex C 61 Immunotherapeutic 61 Clusterin 61 serum antibody 61 Epidermal Growth Factor Receptor 61 Ranolazine 61 Hedgehog Pathway Inhibitor 61 histone acetyltransferase 61 RH1 61 sitaxsentan 61 KRAS mutation 61 SYN# 61 chronic eosinophilic leukemia 61 MNTX 61 antitumor effects 61 adenosine injection 61 pan histone deacetylase 61 antiandrogens 61 cediranib 61 5 HT2A 61 intravesical infusion therapy 61 HuMax CD4 61 CB2 selective receptor agonist 61 Capesaris 61 peptidic compound 61 TG# [003] 61 multiple myeloma MM 61 liposome formulation 61 APTIMA HPV 61 Metastatic Melanoma 61 Sym# 61 PrevOnco ™ 61 intranasal delivery 61 Late Breaker 61 telomerase therapeutic 61 kinase inhibition 61 selective adenosine 61 Inc. NASDAQ HEPH 61 INS# [001] 61 Kamada AAT 61 antitumoral 61 HCV protease 61 MyVax R 61 macrolide antibiotic 61 Selective Electrochemical Tumor Ablation 61 Antiangiogenic 61 REMINYL ® 61 clonidine hydrochloride 61 mapatumumab 61 prucalopride 61 BCR ABL inhibitor 61 Onconase 61 NSCLC tumors 61 HER2 positive metastatic breast 61 pertuzumab 61 Nasdaq IDRA 61 LY# [002] 61 HCV RNA polymerase 61 multi kinase inhibitor 61 oral nucleoside analogue 61 NYSE Amex PBTH 61 visit biotech.com 61 Placebo Controlled Trial 61 dose proportionality 61 assay detects 61 potently inhibits 61 ALN TTR 61 CR# vcMMAE 61 subcutaneous SC 61 Rebif ® 61 Glatiramer acetate 61 linear pharmacokinetics 61 p# biomarker 61 stable nucleic acid 61 aggressive systemic mastocytosis 61 pDNA vaccine 61 Reverset 61 personalized cellular immunotherapy 61 FUSILEV enhances 61 liposome injection 61 NSABP B 61 Abstract Accepted 61 Alfacell proprietary ribonuclease 61 OMAPRO 61 SGLT 61 PET tracers 61 Angiolix 61 reslizumab 61 EpCAM 61 telomerase inhibitor drug 61 TransVax tm 61 Inhalation Solution 61 novel oral anticoagulant 60 Systemic Delivery 60 XL# SAR# 60 sulodexide 60 immunomodulatory agents 60 Phase Ib clinical trials 60 randomized multicenter trial 60 Factor Receptor 60 NASDAQ CYTK announced 60 triphendiol 60 ularitide 60 MOVIPREP R 60 ARB telmisartan 60 treat benign prostatic 60 Cethrin R 60 intravenous methylnaltrexone 60 Dual Opioid 60 Interferon alpha 60 Diabetic Neuropathy 60 5 fluorouracil leucovorin 60 LymphoStat B TM 60 everolimus eluting stents 60 oxaliplatin Eloxatin 60 Alzhemed TM 60 deferiprone 60 axitinib 60 nilotinib Tasigna ® 60 somatostatin analogues 60 #th Annual Interscience 60 IMPACT DCM 60 iroxanadine 60 biostatistical analysis 60 immune modulatory 60 anti CD3 antibody 60 prokinetic agent 60 SCH # 60 BEMA Granisetron 60 TMPRSS2 ERG 60 Campath alemtuzumab 60 #ME# 60 UPLYSO 60 micafungin 60 eniluracil 60 prostaglandin E1 60 TRIOLEX 60 Leuprolide 60 Inc. Nasdaq IMGN 60 Liprotamase 60 retapamulin 60 Phase IIB 60 NMDA antagonist 60 ganaxolone 60 pharmacokinetic parameters 60 Vascular Disrupting Agent 60 pharmacogenomic translational research 60 Protein Kinase C 60 Lp PLA 2 60 AMPK activators 60 Cyclin E 60 Xcytrin R 60 SABCS 60 amino acid residue 60 antiapoptotic 60 evaluating satraplatin 60 enzastaurin 60 interferon IFN 60 posaconazole 60 Randomized Double blind 60 anticancer activity 60 small molecule agonists 60 ToGA 60 XP# XP# 60 small molecule activator 60 PEP# [003] 60 afamelanotide 60 ALB # 60 LAB CGRP 60 BCIRG 60 Submits NDA 60 Annexin V 60 Thrombin 60 Phase 2a clinical trials 60 beta lactam antibiotic 60 bicifadine 60 EndoTAG TM 60 efaproxiral 60 Dyloject TM 60 thetreatment 60 biomodulator 60 CYP#A# CYP#D# 60 PORxin TM 60 brostallicin 60 fidaxomicin Phase 3 60 #I TM# 60 FDG-PET/CT 60 LymphoStat B belimumab 60 recombinant interferon 60 Nucleoside 60 skin sterol 60 dopamine partial agonist 60 heparanase 60 AVADO 60 evaluating bafetinib 60 MET inhibitor 60 acyclovir Lauriad R 60 atacicept 60 Thalomid ® 60 novel immunomodulatory 60 pegylated 60 calcitonin gene related 60 LEP ETU 60 MEK inhibitor 60 menadione 60 QT QTc 60 Virulizin ® 60 NXL# 60 Removab 60 resolvins 60 Lisofylline 60 NovaBay Aganocide compounds 60 clotrimazole 60 Phase IIb III 60 bazedoxifene conjugated estrogens 60 noninfectious uveitis 60 folate receptor 60 PI3 kinase inhibitors 60 EOquin TM phase 60 IAP inhibitor 60 histamine dihydrochloride 60 REVIVE Diabetes 60 dihydrofolate reductase 60 genotypic resistance 60 ASCO GI 60 CCR9 antagonist 60 methylation markers 60 Sipuleucel T 60 GAP #B# 60 evaluating picoplatin 60 acadesine 60 CIMZIA TM 60 SomatoKine 60 refractory colorectal cancer 60 generation radiolabeled antibody 60 administered subcutaneously 60 Aurexis 60 maximally tolerated dose 60 verteporfin 60 humanized anti 60 Symadex 60 interferon γ 60 XmAb# 60 Inc. Nasdaq VRUS 60 predictive biomarker 60 estramustine 60 cetuximab Erbitux 60 NEUVENGE 60 Voreloxin 60 Bosutinib 60 Diabetic Macular Edema DME 60 Monoclonal antibody